Literature DB >> 18954747

Cutaneous T-cell lymphoma.

Frederick Lansigan1, Jaehyuk Choi, Francine M Foss.   

Abstract

Cutaneous T-cell lymphoma comprises a heterogeneous group of lymphoproliferative disorders characterized by clonal expansions of mature, post-thymic T cells that infiltrate the skin. This article discusses the staging, prognosis, and treatment of mycosis fungoides and Sézary syndrome.

Entities:  

Mesh：

Year:  2008        PMID： 18954747     DOI： 10.1016/j.hoc.2008.07.014

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  12 in total

1.  Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.

Authors:  Laura Y McGirt; Christopher Thoburn; Allan Hess; Eric C Vonderheid
Journal:  Photodermatol Photoimmunol Photomed       Date:  2010-08       Impact factor: 3.135

2.  Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma.

Authors:  L Y McGirt; D A Baerenwald; E C Vonderheid; C M Eischen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-06-09       Impact factor: 6.166

3.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

4.  Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Authors:  Narin Apisarnthanarax; Gary S Wood; Seth R Stevens; Sean Carlson; Derek V Chan; Lili Liu; Sarolta K Szabo; Pingfu Fu; Anita C Gilliam; Stanton L Gerson; Scot C Remick; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2012-05

5.  TOX expression and role in CTCL.

Authors:  L Y McGirt; C A Degesys; V E Johnson; J A Zic; J P Zwerner; C M Eischen
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-26       Impact factor: 6.166

6.  Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Authors:  Frederick Lansigan; Diane M Stearns; Francine Foss
Journal:  Cancer Manag Res       Date:  2010-02-05       Impact factor: 3.989

7.  Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.

Authors:  Brian Poligone; Janet Lin; Catherine Chung
Journal:  Core Evid       Date:  2010-12-22

8.  Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism.

Authors:  Rahul Pawar; Anup Kasi Loknath Kumar; Janet Woodroof; Wei Cui; Joseph McGuirk; Sunil Abhyankar; Sid Ganguly; Anurag Singh; Tara Lin; Omar Aljitawi
Journal:  Case Rep Hematol       Date:  2014-12-11

9.  Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.

Authors:  Francine Foss; Bertrand Coiffier; Steven Horwitz; Barbara Pro; H Miles Prince; Lubomir Sokol; Matthew Greenwood; Adam Lerner; Dolores Caballero; Eugeniusz Baran; Ellen Kim; Jean Nichols; Barbara Balser; Julie Wolfson; Sean Whittaker
Journal:  Biomark Res       Date:  2014-09-08

10.  Vorinostat-An Overview.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.